{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"75"}]}],"title":"Total number of hospitalizations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"64"}]}],"title":"Hospitalization for AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}]}],"title":"Planned hospitalization (other than AE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"title":"Ambulatory Surgery"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"404"},{"groupId":"OG001","value":"197"}],"units":"Participants"}],"description":"Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Population: Includes all randomized participants who received at least one dose of study treatment (tucatinib/placebo, trastuzumab, or capecitabine), with participants allocated to the treatment group associated with the regimen actually received.","reportingStatus":"POSTED","timeFrame":"36.1 months","title":"Incidence of Health Resources Utilization","type":"SECONDARY","unitOfMeasure":"hospitalizations"}